MannKind Corporation (NASDAQ:MNKD) Presents Encouraging Afrezza Clinical Study Data At The ADA Virtual Scientific Summit

MannKind Corporation (NASDAQ:MNKD) has announced new Afrezzza Inhalation powder clinical study results. The company presented the data at this year’s American Diabetes Associations 80th Scientific Session held between June 12 and June 16, 2020.

MannKind presents Afreza study data at ADA summit

The data comprised a full post hoc analysis of four different studies evaluating the safety and efficacy of Afrezza dosing in patients with type 1 diabetes. Equally, the presented data also included an analysis showing that Afrezza treatment is related to loss in weight in type 2 diabetes. This is relative to gain in weight when treated with mealtime insulin. Similarly, the data showed that in the evaluation of the two-year study’s safety, there were considerable FEV1 changes during Afrezza treatment.

David Kendall, the Chief Medical officer of Mannkind, indicated that they were delighted to present the clinical studies showing the safety and efficacy of Afrezza during this year’s ADA Scientific conference. Kendall added that the studies offer additional support for the clinical safety and effectiveness of Afrezza treatment. Equally, it provides a significant understanding of effective Afrezza dosing as well as an impact on body weight. The chief medical officer stated that the data shows significant clinical outcomes in patients after shifting to Afrezza therapy.

Results show a reduction in A1C levels in type 2 diabetes

Mark Kipnes, who was the lead author of the poster, presented the data at the ADA Scientific Summit. Kipnes presented the results from the investigational-instigated observational study. The study evaluated glucose control and quality of life in patients with type 2 diabetes who received mealtime insulin injections before. After shifting to Afrezza therapy, patients were observed for 14 days and quality of life, hypoglycemia rates, as well as glucose control, evaluated.

The study participants experienced around 0.8% reduction levels in A1C after the 14 weeks of treatment. This was after converting from to Afrezza therapy from injected mealtime insulin. Results indicate that when Afrezza therapy is combined with consistent glucose monitoring, it can enhance general glucose control and maintain time in range.